Advanced Prostate Cancer: How PSMA Testing Guides the Choice of Lutetium Treatment

In some advanced forms of oncological disease, the choice of treatment depends not only on the location of metastases, but also on the presence of certain biological targets on the surface of tumour cells. For this reason, modern diagnostic investigations can directly influence therapeutic decisions.

In the case of advanced prostate cancer, doctors may use PSMA testing, an imaging method that identifies cells expressing the prostate-specific membrane antigen. If the results show that the disease presents this characteristic, and the patient meets the necessary criteria, lutetium therapy may be considered — a radioligand treatment that binds to tumour cells and delivers radiation directly at a local level. The recommendation of this approach takes into account the stage of the disease, previous treatments, investigation results, and the patient's general condition.

Testing and treatment are closely linked: the investigation confirms the existence of the biological target, and the therapy relies on this target to act with greater precision. In recent years, the indications for lutetium therapy have been expanded for certain categories of patients with metastatic disease; however, the final decision rests with the multidisciplinary oncology team.

Article supported by SANADOR, more details at www.sanador.ro.